Market Size of Malaysia Oral Anti-Diabetic Drug Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 274 Million |
| Market Size (2028) | USD 333 Million |
| CAGR (2024 - 2029) | > 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Malaysia Oral Anti-Diabetic Drug Market Analysis
The Malaysia Oral Anti-Diabetic Drug Market size is estimated at USD 274 million in 2024, and is expected to reach USD 333 million by 2028, growing at a CAGR of greater than 3% during the forecast period (2024-2028).
According to the Health Ministry, one in five Malaysians, or around 3.9 million adults and older, have diabetes. There are more young people with diabetes. The prevalence of diabetes is rising among younger people, with the number of diabetics in this age group more than doubling in the past 15 years.
Diabetes complications, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, are becoming more prevalent due to the expanding diabetes population. Most coronavirus mortality in Malaysia is caused by underlying comorbidities, with diabetes and hypertension at the top.
Diabetes among young people is on the rise. With the number of patients between the ages of 18 and 40 having doubled over the previous 15 years, younger individuals are developing diabetes. The burden of diabetes and its consequences, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, is increasing as the number of people with diabetes grows.
